What is it about?
Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. The study is evaluating the effect and cost of this new medications on bad cholesterol and cardiovascular disease risk.
Featured Image
Why is it important?
The use of this medication reduces the bad cholesterol and cardiovascular disease risk
Perspectives
People who have high bad cholesterol and cardiovascular disease risk could benefit using this new medication
Andrea Manfrin
University of Sussex
Read the Original
This page is a summary of: A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk, ClinicoEconomics and Outcomes Research, October 2018, Dove Medical Press,
DOI: 10.2147/ceor.s172838.
You can read the full text:
Resources
Contributors
The following have contributed to this page
